We are making progress towards the commercial launch of EpiKidney.
Shipping conditions have been verified.
Currently, the tissue has weak expression of OAT3, an important transporter.
We are trying to induce higher expression of OAT3.
In addition, basal expression of Kidney injury molecule-1 (KIM1) was higher than we expected.
By adjusting the media formulation, we were able to dramatically decrease expression of KIM-1.
We are currently verifying this new media formulation.
상세문의는 상담실로 해주시기바랍니다. |
Home > 공지사항 
이전글
다음글
